Display options
Cite
Budiawan H, Salavati A, Kulkarni HR, et al. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging. 2013;4(1):39-52
Budiawan, H., Salavati, A., Kulkarni, H. R., & Baum, R. P. (2013). Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. American journal of nuclear medicine and molecular imaging, 4(1), 39-52.
Budiawan, Hendra, et al. "Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis." American journal of nuclear medicine and molecular imaging vol. 4,1 (2013): 39-52.
Budiawan H, Salavati A, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):39-52. eCollection 2013. PMID: 24380044; PMCID: PMC3867728.
Copy Download .nbib Format: NLM
Share it on

Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):39-52. eCollection 2013.

Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.

American journal of nuclear medicine and molecular imaging

Hendra Budiawan, Ali Salavati, Harshad R Kulkarni, Richard P Baum

Affiliations

  1. THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence Zentralklinik Bad Berka, Germany ; Department of Nuclear Medicine, Mochtar Riady Comprehensive Cancer Centre - Siloam Hospitals Semanggi Jakarta, Indonesia.
  2. THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence Zentralklinik Bad Berka, Germany ; Department of Radiology, University of Pennsylvania Philadelphia, USA.
  3. THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence Zentralklinik Bad Berka, Germany.

PMID: 24380044 PMCID: PMC3867728

Abstract

The overall survival rate of non-radioiodine avid differentiated (follicular, papillary, medullary) thyroid carcinoma is significantly lower than for patients with iodine-avid lesions. The purpose of this study was to evaluate toxicity and efficacy (response and survival) of peptide receptor radionuclide therapy (PRRT) in non-radioiodine-avid or radioiodine therapy refractory thyroid cancer patients. Sixteen non-radioiodine-avid and/or radioiodine therapy refractory thyroid cancer patients, including follicular thyroid carcinoma (n = 4), medullary thyroid carcinoma (n = 8), Hürthle cell thyroid carcinoma (n = 3), and mixed carcinoma (n = 1) were treated with PRRT by using (90)Yttrium and/or (177)Lutetium labeled somatostatin analogs. (68)Ga somatostatin receptor PET/CT was used to determine the somatostatin receptor density in the residual tumor/metastatic lesions and to assess the treatment response. Hematological profiles and renal function were periodically examined after treatment. By using fractionated regimen, only mild, reversible hematological toxicity (grade 1) or nephrotoxicity (grade 1) were seen. Response assessment (using EORTC criteria) was performed in 11 patients treated with 2 or more (maximum 5) cycles of PRRT and showed disease stabilization in 4 (36.4%) patients. Two patients (18.2%) showed partial remission, in the remaining 5 patients (45.5%) disease remained progressive. Kaplan-Meier analysis resulted in a mean survival after the first PRRT of 4.2 years (95% CI, range 2.9-5.5) and median progression free survival of 25 months (inter-quartiles: 12-43). In non-radioiodine-avid/radioiodine therapy refractory thyroid cancer patients, PRRT is a promising therapeutic option with minimal toxicity, good response rate and excellent survival benefits.

Keywords: 68Ga-DOTA-TATE; 68Ga-DOTA-TOC; Peptide radionuclide receptor therapy; non-radioiodine-avid; positron emission tomography (PET); somatostatin receptors; survival analysis; thyroid cancer

References

  1. Cancer. 1997 Dec 15;80(12 Suppl):2436-57 - PubMed
  2. Cancer. 1984 Aug 15;54(4):657-62 - PubMed
  3. Radiat Res. 2003 Apr;159(4):502-10 - PubMed
  4. Lancet Oncol. 2007 Feb;8(2):148-56 - PubMed
  5. Cancer. 2009 May 15;115(10):2052-62 - PubMed
  6. Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):67-77 - PubMed
  7. Recent Results Cancer Res. 2013;194:379-84 - PubMed
  8. J Clin Endocrinol Metab. 2001 May;86(5):2161-9 - PubMed
  9. Am J Surg. 1996 Dec;172(6):692-4 - PubMed
  10. Thyroid Res. 2009 Jan 27;2(1):1 - PubMed
  11. Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):22-32 - PubMed
  12. J Clin Endocrinol Metab. 2004 Nov;89(11):5362-8 - PubMed
  13. J Biol Chem. 2000 Sep 1;275(35):27386-92 - PubMed
  14. J Nucl Med. 2007 Oct;48(10):1741-8 - PubMed
  15. Thyroid. 1994 Fall;4(3):243-8 - PubMed
  16. Hell J Nucl Med. 2009 May-Aug;12(2):161-4 - PubMed
  17. Eur J Cancer. 1999 Dec;35(13):1773-82 - PubMed
  18. Nucl Med Biol. 2008 Aug;35(6):673-8 - PubMed
  19. Eur J Nucl Med Mol Imaging. 2012 Aug;39(8):1271-7 - PubMed
  20. Semin Nucl Med. 2011 Mar;41(2):139-48 - PubMed
  21. J Clin Endocrinol Metab. 2005 Nov;90(11):6077-84 - PubMed
  22. Trends Genet. 2000 Apr;16(4):168-74 - PubMed
  23. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):61-7 - PubMed
  24. Trends Endocrinol Metab. 2006 Jan-Feb;17(1):19-25 - PubMed
  25. J Clin Oncol. 2001 May 15;19(10):2616-25 - PubMed
  26. Trends Mol Med. 2006 Sep;12(9):440-50 - PubMed
  27. Med Phys. 2008 Mar;35(3):1123-34 - PubMed
  28. Thyroid. 2009 Apr;19(4):381-9 - PubMed
  29. Ann Nucl Med. 2012 May;26(4):365-9 - PubMed
  30. Recent Results Cancer Res. 2013;194:519-36 - PubMed
  31. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6696-702 - PubMed
  32. J Nucl Med. 2011 Dec;52(12):1864-70 - PubMed
  33. J Nucl Med. 1996 Aug;37(8):1388-92 - PubMed
  34. J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9 - PubMed
  35. J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62 - PubMed
  36. Lancet. 2003 Feb 8;361(9356):501-11 - PubMed
  37. Semin Nucl Med. 2012 May;42(3):190-207 - PubMed
  38. Biochem J. 1994 Mar 15;298 Pt 3:537-41 - PubMed
  39. Thyroid. 1999 May;9(5):421-7 - PubMed
  40. Cancer Res. 1999 Apr 1;59(7 Suppl):1676s-1684s - PubMed
  41. Eur J Surg Oncol. 2007 Sep;33(7):902-6 - PubMed
  42. J Clin Endocrinol Metab. 1999 Jul;84(7):2449-57 - PubMed
  43. J Nucl Med. 2000 Apr;41(4):636-42 - PubMed
  44. Oncologist. 2008 May;13(5):539-47 - PubMed
  45. J Clin Endocrinol Metab. 2006 Jan;91(1):313-9 - PubMed
  46. Int J Clin Exp Med. 2012;5(4):363-6 - PubMed

Publication Types